The company is effectively ceasing operations as a going concern with a 94% workforce reduction and no remaining pipeline disclosed. The strategic alternatives process will determine whether the company is sold, liquidates, or finds another outcome. Monitor for any definitive agreement or dissolution filing.
Drugs in focus
ARTV drug pipeline →AB-101
● Neutral Named in this 8-K/A- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $4.06entry
- T+1 · 6d ago +0.25%α −1.07% · $4.07
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics filed an amended 8-K providing cost estimates for its wind-down, which includes discontinuing its lead drug candidate AlloNK (AB-101) and reducing its workforce by approximately 94%. The company estimates $10M-$15M in contract termination costs for clinical trial close-outs and $17M-$20M in workforce reduction costs, with most charges expected in Q4 2026. The company continues to explore strategic alternatives to maximize stockholder value.
Key Facts
- Board approved discontinuation of AlloNK (AB-101) development
- Workforce reduction of approximately 94% of current employee base
- Estimated $10M to $15M in contract termination and clinical trial close-out costs
- Estimated $17M to $20M in workforce reduction costs (severance, benefits, payroll taxes)
- Workforce reduction expected to complete in Q1 2027
- Significant majority of wind-down costs expected in Q4 2026
- Company is conducting a process to explore strategic alternatives
Financial Impact
Total estimated wind-down costs of $27M to $35M, representing 13% to 17% of the company's $202M market cap
Risk Factors
- No remaining clinical pipeline after AlloNK discontinuation
- 94% workforce reduction leaves minimal operational capacity
- Strategic alternatives process may not result in a value-maximizing outcome
- Additional unanticipated wind-down costs may arise
- Potential delisting risk given minimal ongoing business
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001193125-26-453580 |
| Document: 0001193125-26-453580-index-headers.html | 0001193125-26-453580 |
| Document: 0001193125-26-453580-index.html | 0001193125-26-453580 |
| Document: 0001193125-26-453580.txt | 0001193125-26-453580 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Viewing Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers